• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Oaktree Gcp Fund Delaware Holdings, L.P.

    11/20/23 9:12:13 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMPL alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Oaktree GCP Fund Delaware Holdings, L.P.

    (Last) (First) (Middle)
    333 S. GRAND AVENUE,
    28TH FLOOR

    (Street)
    LOS ANGELES CA 90071

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    11/10/2023
    3. Issuer Name and Ticker or Trading Symbol
    IMPEL PHARMACEUTICALS INC [ IMPL ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Warrants (1) (1) Common Stock 2,671,763(2)(3) $0.01 I See Footnote(4)(5)
    1. Name and Address of Reporting Person*
    Oaktree GCP Fund Delaware Holdings, L.P.

    (Last) (First) (Middle)
    333 S. GRAND AVENUE,
    28TH FLOOR

    (Street)
    LOS ANGELES CA 90071

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Oaktree Diversified Income Fund Inc.

    (Last) (First) (Middle)
    333 S. GRAND AVENUE,
    28TH FLOOR

    (Street)
    LOS ANGELES CA 90071

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Oaktree AZ Strategic Lending Fund, L.P.

    (Last) (First) (Middle)
    333 S. GRAND AVENUE,
    28TH FLOOR

    (Street)
    LOS ANGELES CA 90071

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Oaktree Loan Acquisition Fund, L.P.

    (Last) (First) (Middle)
    333 S. GRAND AVENUE,
    28TH FLOOR

    (Street)
    LOS ANGELES CA 90071

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Oaktree LSL Fund Holdings EURRC S.a.r.l.

    (Last) (First) (Middle)
    333 S. GRAND AVENUE,
    28TH FLOOR

    (Street)
    LOS ANGELES CA 90071

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Oaktree LSL Fund Delaware Holdings EURRC, L.P.

    (Last) (First) (Middle)
    333 S. GRAND AVENUE,
    28TH FLOOR

    (Street)
    LOS ANGELES CA 90071

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Oaktree PRE Life Sciences Fund, L.P.

    (Last) (First) (Middle)
    333 S. GRAND AVENUE,
    28TH FLOOR

    (Street)
    LOS ANGELES CA 90071

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Oaktree Capital Group, LLC

    (Last) (First) (Middle)
    333 S. GRAND AVENUE,
    28TH FLOOR

    (Street)
    LOS ANGELES CA 90071

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Atlas OCM Holdings, LLC

    (Last) (First) (Middle)
    333 S. GRAND AVENUE,
    28TH FLOOR

    (Street)
    LOS ANGELES CA 90071

    (City) (State) (Zip)
    Explanation of Responses:
    1. The Warrants are exercisable at any time prior to the earlier to occur of: (a) the seventh anniversary of the date of issuance or (b) a change of control. 1,335,881 Warrants were issued on September 5, 2023, 445,293 Warrants were issued on October 2, 2023, 445,295 Warrants were issued on October 6, 2023, 222,647 Warrants were issued on November 3, 2023, and 222,647 Warrants were issued on November 10, 2023.
    2. The reported amount reflects (i) 29,282 Warrants held directly by Oaktree-TCDRS Strategic Credit, LLC, (ii) 23,673 Warrants held directly by Oaktree-Forrest Multi-Strategy, LLC, (iii) 14,241 Warrants held directly by Oaktree-TBMR Strategic Credit Fund C, LLC, (iv) 22,309 Warrants held directly by Oaktree-TBMR Strategic Credit Fund F, LLC, (v) 36,417 Warrants held directly by Oaktree-TBMR Strategic Credit Fund G, LLC, (vi) 36,657 Warrants held directly by Oaktree-TSE 16 Strategic Credit, LLC, (vii) 10,847 Warrants held directly by INPRS Strategic Credit Holdings, LLC, (viii) 183,470 Warrants held directly by Oaktree Gilead Investment Fund AIF (Delaware), L.P., (ix) 700,484 Warrants held directly by Oaktree Specialty Lending Corporation, (x) 16,297 Warrants held directly by Oaktree GCP Fund Delaware Holdings, L.P., (xi) 53,488 Warrants held directly by Oaktree Diversified Income Fund Inc., (xii) 348,478 Warrants held directly by Oaktree AZ Strategic Lending Fund, L.P.,
    3. (continued from Footnote 2) (xiii) 135,861 Warrants held directly by Oaktree Loan Acquisition Fund, L.P., (xiv) 373,618 Warrants held directly by Oaktree LSL Fund Holdings EURRC S.a r.l., (xv) 203,801 Warrants held directly by Oaktree LSL Fund Delaware Holdings EURRC, L.P., (xvi) 228,088 Warrants held directly by Oaktree PRE Life Sciences Fund, L.P. (each of the foregoing, an "Atlas Entity," and together, the "Atlas Entities"), and (xvii) 254,752 Warrants held directly by Oaktree Strategic Credit Fund (and, together with the Atlas Entities, the "Oaktree Holders," and each an "Oaktree Holder").
    4. Oaktree Capital Group, LLC, in its capacity as the indirect manager of Oaktree Strategic Credit Fund, may be deemed to beneficially own the Warrants held directly by Oaktree Strategic Credit Fund. Atlas OCM Holdings, LLC, in its capacity as the indirect manager of the Atlas Entities, may be deemed to beneficially own the Warrants held directly by the Atlas Entities. Brookfield Corporation, in its capacity as the indirect owner of the class A units of Oaktree Capital Group, LLC, may be deemed to beneficially own the Warrants held directly by Oaktree Strategic Credit Fund. BAM Partners Trust, in its capacity as the sole owner of Class B Limited Voting Shares of Brookfield Corporation, may be deemed to beneficially own the Warrants held directly by Oaktree Strategic Credit Fund. Brookfield Asset Management ULC, in its capacity as the indirect owner of Class A units of Atlas OCM Holdings, LLC, may be deemed to beneficially own the Warrants held directly by the Atlas Entities.
    5. Neither the filing of this Form 3 nor any of its contents shall be deemed to constitute an admission by any of the Reporting Persons that it is the beneficial owner of any of the Warrants referred to herein for the purposes of Section 16 of the Securities and Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed by each Reporting Person, other than each Oaktree Holder with respect to securities reported as directly held by such Oaktree Holder.
    Remarks:
    Form 2 of 3.
    Oaktree GCP Fund Delaware Holdings, L.P., By: Oaktree Global Credit Plus Fund GP, L.P., Its: GP, By: Oaktree Global Credit Plus Fund GP Ltd., Its: GP, By: Oaktree Capital Management, L.P., Its: Director, /s/ Henry Orren, Senior Vice President 11/20/2023
    Oaktree Diversified Income Fund, Inc., By: Oaktree Fund Advisers, LLC, Its: Investment Adviser, /s/ Henry Orren, Senior Vice President 11/20/2023
    Oaktree AZ Strategic Lending Fund, L.P., By: Oaktree AZ Strategic Lending Fund GP, L.P., Its: GP, By: Oaktree Fund GP IIA, LLC, Its: GP, By: Oaktree Fund GP II, L.P., Its: Managing Member, /s/ Henry Orren, Authorized Signatory 11/20/2023
    Oaktree Loan Acquisition Fund, L.P., By: Oaktree Fund GP IIA, LLC, Its: GP,By: Oaktree Fund GP II, L.P., Its: Managing Member,/s/ Henry Orren, Authorized Signatory 11/20/2023
    Oaktree LSL Fund Holdings EURRC S.a r.l., /s/ Martin Eckel, Manager 11/20/2023
    Oaktree LSL Fund Delaware Holdings EURRC, L.P., By: Oaktree Life Sciences Lending Fund GP, L.P., Its: GP, By: Oaktree Life Sciences Lending Fund GP Ltd., Its: GP, By: Oaktree Capital Management, L.P., Its: Director, /s/ Henry Orren, SVP 11/20/2023
    Oaktree PRE Life Sciences, L.P., By: Oaktree PRE Life Sciences Fund GP, L.P., Its: GP, By: Oaktree Fund GP IIA, LLC, Its: GP, By: Oaktree Fund GP II, L.P., Its: Managing Member, /s/ Henry Orren, Authorized Signatory 11/20/2023
    Oaktree Capital Group, LLC, /s/ Henry Orren, Senior Vice President 11/20/2023
    Atlas OCM Holdings, LLC, /s/ Henry Orren, Senior Vice President 11/20/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IMPL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMPL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IMPL
    Leadership Updates

    Live Leadership Updates

    See more
    • Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer

      SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Michael W. Kalb, CPA, as Chief Financial Officer, effective May 10, 2023. "Michael brings an outstanding track record of executive leadership in finance, capital raising, business development and operations management to Impel Pharmaceuticals," said Adrian Adams, Chairman of the Board and Chief Executive Officer of Impel Pharmaceuticals. "We are delighted to welcome Michael to Impel's leadership team and believe that

      5/10/23 8:00:00 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors

      SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Darren Cline to the Board of Directors. Mr. Cline brings more than 30 years of experience in the biopharmaceutical industry, including extensive commercialization and operational expertise. The Company also announced the departure of H. Stewart Parker, with both changes to the Board effective immediately. "It is my pleasure to welcome Darren to the Impel Board of Directors," said Adrian Adams, Chairman of the Board and Chief Executiv

      4/12/23 4:01:00 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMPL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Smith Brandon D

      3 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)

      12/26/23 4:32:40 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vivo Capital Viii, Llc sold $74,131 worth of shares (575,000 units at $0.13) (SEC Form 4)

      4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)

      12/19/23 6:00:01 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Brookfield Corp /On/

      4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)

      12/4/23 9:00:40 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMPL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate Sale

      Patient Access to Trudhesa® to Continue Uninterrupted Sufficient Liquidity to Fund Day to Day Operations During Court-Supervised Process SEATTLE, Dec. 19, 2023 /PRNewswire/ -- Impel Pharmaceuticals Inc. (OTCQX:IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it is pursuing a sale of the Company and has entered into an agreement with JN BIDCO LLC to serve as the "stalking horse" bidder to acquire the Company and its assets.

      12/19/23 11:10:00 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Impel Pharmaceuticals Announces Exploration of Strategic Alternatives

      SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it has initiated an exploration of strategic alternatives. As part of this process, the Company plans to consider a wide range of options with a focus on maximizing shareholder value, including a potential sale of assets of the Company, a sale of all of the Company, a merger or other strategic transactions. As the Company explores strategic options, Impel continues to provide full commercial support

      10/5/23 8:00:00 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

      Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. "Following our strategic reprioritization to focus the company on maximizing the growth potential of

      5/12/23 8:00:00 AM ET
      $IMPL
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMPL
    SEC Filings

    See more

    $IMPL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • SEC Form EFFECT filed by Impel Pharmaceuticals Inc.

      EFFECT - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)

      2/16/24 12:15:09 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Impel Pharmaceuticals Inc.

      S-8 POS - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)

      2/14/24 5:21:28 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Impel Pharmaceuticals Inc.

      S-8 POS - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)

      2/14/24 5:19:30 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

      Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

      9/13/21 2:21:35 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

      Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

      9/7/21 1:04:43 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMPL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Impel Pharmaceuticals Inc. (Amendment)

      SC 13D/A - IMPEL PHARMACEUTICALS INC (0001445499) (Subject)

      12/4/23 5:12:05 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Impel Pharmaceuticals Inc. (Amendment)

      SC 13D/A - IMPEL PHARMACEUTICALS INC (0001445499) (Subject)

      11/15/23 4:06:46 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Impel Pharmaceuticals Inc. (Amendment)

      SC 13D/A - IMPEL PHARMACEUTICALS INC (0001445499) (Subject)

      10/6/23 5:10:06 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMPL
    Financials

    Live finance-specific insights

    See more

    $IMPL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

      Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. "Following our strategic reprioritization to focus the company on maximizing the growth potential of

      5/12/23 8:00:00 AM ET
      $IMPL
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023

      SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m. ET to report its first quarter 2023 financial results and provide a business update. To access the live conference call, please register using the conference link: https://register.vevent.com/register. A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the webcast and accompan

      5/5/23 8:00:00 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

      Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue Finished Year at $12.7 Million; Increased 62% in Q4 vs. Q3 2022 to $5 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, March 24, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update. "We continued to see strong growth in Trudhesa® prescriptions as we moved i

      3/24/23 8:17:18 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cowen initiated coverage on Impel NeuroPharma with a new price target

      Cowen initiated coverage of Impel NeuroPharma with a rating of Outperform and set a new price target of $35.00

      5/18/21 7:57:51 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Impel NeuroPharma with a new price target

      Wedbush initiated coverage of Impel NeuroPharma with a rating of Outperform and set a new price target of $21.00

      5/18/21 7:55:03 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Impel NeuroPharma with a new price target

      Guggenheim initiated coverage of Impel NeuroPharma with a rating of Buy and set a new price target of $32.00

      5/18/21 7:55:03 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care